35.1 C
Delhi
Thursday, June 20, 2024

EU States Approve 14th Sanctions Package Against Russia, Diplomats Say

European Union countries have approved a 14th...

Monsoon Advances, Set To Bring Relief From Heatwave

The monsoon is advancing after stalling for...

Uzbekistan says 18 kids killed due to cough syrup by India’s Biotech

AfricaUzbekistan says 18 kids killed due to cough syrup by India's Biotech

Centre seeks causality status as Uzbekistan links deaths of 18 kids to Indian syrup made by Marion Biotech, registered in 2012 in Uzbekistan.

The Union government has sought a causality status after Uzbekistan on Wednesday linked the deaths of 18 kids to Indian cough syrup Dok-1 Max Syrup produced by Noida-based Marion Biotech, sources said.  Dok-1 Max Syrup is a combination of three medical ingredients paracetamol, guaifenesin, and phenylephrine hydrochloride, but ethylene glycol is the toxic ingredient in this syrup.

The health ministry of Uzbekistan has alleged that 18 children have died in the country after consuming medicines manufactured by an Indian pharmaceutical company, months after a similar incident was reported in Gambia. The company in question, Marion Biotech, was registered in 2012 in Uzbekistan.

To date, 18 out of 21 children with acute respiratory disease have died as a result of taking Doc-1 Max syrup, the ministry said.

“It was found that the deceased children, before admission to hospital treatment, took this drug at home for 2-7 days 3-4 times a day, 2.5-5 ml, which exceeds the standard dose of the drug for children,” the statement noted.

Earlier, 4 cough syrups by an Indian pharma firm were linked to the deaths of 66 children in Gambia, Africa.  It added that primary laboratory studies have shown the presence of ethylene glycol—the deadly chemical which was held responsible for deaths in the Gambia—in the Dok-1 Max syrup.

Meanwhile, sources in the Central Drugs Standard Control Organisation (CDSCO) have revealed that this particular syrup is currently not being sold in the Indian market.

Check out our other content

Check out other tags:

Most Popular Articles